10x Genomics, Inc. ($TXG) Stock Forecast: Down 5.2% Today

What is 10x Genomics, Inc.?

10x Genomics (TXG) is a biotechnology company known for its innovative solutions in genomics, enabling researchers to study complex biological systems at unprecedented resolution.

Why is 10x Genomics, Inc. going down?

TXG stock is down 5.2% on Oct 30, 2025 16:36

• The bearish movement in TXG today could be attributed to profit-taking by investors who may have been anticipating a positive earnings report.
• Despite expectations of beating earnings estimates, market sentiment may have shifted due to broader economic concerns or sector-specific challenges impacting biotech stocks.
• It's possible that some investors are taking a cautious approach ahead of the earnings release, leading to a temporary dip in TXG's stock price.

TXG Price Chart

TXG Technical Analysis

TXG News

10x Genomics ( TXG ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

https://www.zacks.com/stock/news/2781581/10x-genomics-txg-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 5.0% Today

Ethereum ($ETH) Crypto Forecast: Down 8.2% Today

Ethereum Classic ($ETC) Crypto Forecast: Down 8.4% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.2% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 8.2% Today

Reddit Inc ($RDDT) Stock Forecast: Down 8.1% Today

Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 13.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 6.8% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 9.1% Today

ZCash ($ZEC) Crypto Forecast: Down 5.1% Today

10x Genomics, Inc. Price History

08.07.2025 - TXG Stock was down 6.8%

• Despite surpassing Q2 earnings and revenue estimates significantly, TXG experienced a bearish movement.
• Investors might have had high expectations already priced into the stock, leading to a sell-off post-earnings.
• The market might be reacting to forward-looking guidance or other factors not captured in the earnings report, causing the bearish movement.
• This could be a classic case of "buy the rumor, sell the news" scenario, where investors take profits after a positive earnings surprise.

30.09.2024 - TXG Stock was up 5.8%

• Despite a decrease in instrument sales affecting Q3 earnings, TXG experienced a significant bullish surge today.
• Investor sentiment may be buoyed by the potential for growth in consumable sales, which helped mitigate the drop in instrument sales.
• The market appears to appreciate the company's emphasis on consumables as a more reliable source of revenue compared to instrument sales.
• This uptick in activity could suggest that investors have confidence in 10x Genomics' capability to overcome obstacles and expand into new revenue streams.

21.09.2025 - TXG Stock was up 5.7%

• 10x Genomics (TXG) stock experienced a robust bullish movement, rising by 11.1%.
• The recent above-average trading volume suggests growing investor interest in the company's stock.
• Despite the positive performance, there are concerns about the sustainability of this strength in the short term given recent trends in earnings estimate revisions, which may prompt caution among investors.
• It is advisable for investors to closely track any updates in earnings estimates to assess the future direction of TXG's stock price.

31.09.2024 - TXG Stock was down 3.8%

• Despite a loss in the third quarter, 10x Genomics (TXG) exceeded market expectations for earnings per share, potentially triggering a positive market sentiment initially.
• Nevertheless, a drop in instrument sales for the gene sequencing technology in the third quarter resulted in a negative trend for TXG stock, raising concerns among investors regarding revenue growth prospects.
• The conflicting outcomes of surpassing earnings expectations while encountering a decrease in sales underscored the market's emphasis on revenue generation and future growth potential for 10x Genomics, leading to the downward movement in the stock price.

09.04.2025 - TXG Stock was down 1.7%

• The reported Q1 loss by TXG may have raised concerns among investors about the company's financial health, leading to a bearish movement in the stock.
• Despite topping revenue estimates, the larger-than-expected loss could have overshadowed the positive revenue performance, contributing to the downward trend in TXG's stock price.
• Investors might be cautious about the future prospects of TXG, waiting for more clarity on the factors behind the reported loss and its potential impact on the company's growth trajectory.

05.01.2025 - TXG Stock was up 5.7%

• Despite worries about negative earnings expectations, 10x Genomics (TXG) surprised the market with a strong bullish performance, indicating positive investor sentiment.
• Trades by Ark Invest, led by Cathie Wood, did not directly impact 10x Genomics (TXG) stock, allowing it to stand out positively in today's market.
• The bullish movement in 10x Genomics (TXG) stock may be linked to favorable internal developments, suggesting potential positive upcoming earnings despite initial apprehensions.

29.04.2025 - TXG Stock was up 5.4%

• Analysts have established an average price target for TXG, signaling a potential upside of 43.1% and demonstrating favorable sentiment toward the stock.
• Upward revisions in earnings estimates for TXG may have played a role in the market's bullish movement.
• Investor confidence in TXG's growth prospects and advancements in gene sequencing technology likely contributed to the optimistic market sentiment.

14.04.2025 - TXG Stock was down 5.0%

• Despite analysts forecasting a potential upside of 55.9% for TXG, the stock exhibited a bearish movement today.
• The Q1 earnings report revealed a 20% earnings surprise and 16.24% revenue beat, which could have initially fueled positive investor sentiment.
• However, undisclosed factors within the report likely triggered a negative market response, resulting in today's bearish movement in TXG.
• Concerns about the company's future prospects or broader market conditions may be contributing to the decline in TXG's stock price.

14.01.2025 - TXG Stock was up 7.6%

• Despite posting a Q4 loss and missing EPS estimates, 10x Genomics (TXG) had a strong bullish movement, indicating that investors are focusing on other positive aspects of the company.
• The company's revenue exceeding estimates could have contributed to the bullish movement, showing potential growth opportunities and market confidence in its products and services.
• The market might be optimistic about 10x Genomics' future prospects, especially with its 2025 sales guidance, even though it falls slightly below consensus, suggesting long-term growth potential.
• Investors may be overlooking short-term profitability concerns and focusing more on the company's revenue performance and strategic direction, driving the bullish movement in the stock.

13.01.2025 - TXG Stock was down 5.7%

• TXG reported a Q4 loss, which was lower than expected by 25%.
• Despite topping revenue estimates slightly, the market reacted negatively to the earnings miss.
• Investors might be concerned about the company's future performance and profitability, leading to the bearish movement in the stock price.
• The market sentiment towards TXG seems to be influenced by the disappointing earnings report, causing a sell-off in the stock.

30.09.2025 - TXG Stock was down 5.2%

• The bearish movement in TXG today could be attributed to profit-taking by investors who may have been anticipating a positive earnings report.
• Despite expectations of beating earnings estimates, market sentiment may have shifted due to broader economic concerns or sector-specific challenges impacting biotech stocks.
• It's possible that some investors are taking a cautious approach ahead of the earnings release, leading to a temporary dip in TXG's stock price.

02.04.2025 - TXG Stock was up 5.1%

• Despite concerns about negative earnings, investors may be optimistic about potential future growth prospects or other positive developments within the company.
• The bullish movement could indicate that investors are looking beyond short-term earnings and focusing on the long-term potential of 10x Genomics.
• Market sentiment may have been swayed by positive industry trends or broader market conditions, leading to the bullish movement in TXG's stock price.